CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?-Reference-Cited by-同舟云学术

CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?

Published:2020-12 Issue:1 Volume:7 Page:
ISSN:2054-9369
Container-title:Military Medical Research
language:en
Short-container-title:Military Med Res

Author:

Li Zi-Qing^ORCID,Li Chao-Hong

Abstract

AbstractIn October 2020, Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology. Although CRISPR technology has developed rapidly in the last decade, there are still many uncertainties before eventual use in clinical settings. In this mini review, we summarize the current efforts in addressing the limitations of CRISPR technology and future directions.

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40779-020-00292-2.pdf

Reference15 articles.

1. Lander ES. The heroes of CRISPR. Cell. 2016;164(1–2):18–28.

2. Dort EN, Tanguay P, Hamelin RC. CRISPR/Cas9 gene editing: an unexplored frontier for forest pathology. Front Plant Sci. 2020;11:1126.

3. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387.